health
Daily Pill Can Double Survival Time for World's Deadliest Cancer, Trial Shows
Experts Hail Daraxonrasib as 'Gamechanger' for Patients with Advanced Pancreatic Cancer
TL;DR
- A daily pill called daraxonrasib has doubled survival time in patients with advanced pancreatic cancer, according to a clinical trial.
- The drug targets the Kras protein, a key driver in nearly all pancreatic cancers, by gluing molecules to shut it down.
- In a trial of 500 patients, those taking daraxonrasib lived an average of 13.2 months, compared to 6.6-6.7 months for those on chemotherapy.
- Experts are calling the results a 'gamechanger' and a significant breakthrough, with potential implications for other cancer types fueled by Ras genes.
- The discovery offers new hope for patients with pancreatic cancer, a disease with historically limited treatment options and low survival rates.